Trial Profile

A retrospective, multicenter chart review assessing real-world outcomes associated with reslizumab in U.S. clinical practice in adults with Severe Eosinophilic Asthma (Sea)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2020 Results assessing real-world outcomes associated with reslizumab use in patients with severe eosinophilic asthma in US clinical practice published in the Chest
20 May 2020 Results (n=67) of subgroup analysis, evaluating Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma, presented at the 116th International Conference of the American Thoracic Society
16 Mar 2020 Results assessing health resource utilization and Improved efficacy outcomes published at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com